24 mars 2021 | International, Aérospatial
L3Harris to provide advanced electronic warfare system for F-16 fighter
L3Harris Technologies has secured a contract to develop a new advanced electronic warfare (EW) system for F-16 fighter jet'.
2 juin 2020 | International, Naval
All aboard the Sea Train!
Imagine the following scenario.
Four medium-sized U.S. Navy vessels depart from a port along the United States' coast. There's no crew aboard any of them.
About 15 nautical miles off the coast, the four vessels rendezvous, autonomously arranging themselves in a line. Using custom mechanisms, they attach to each other to form a train, except they're in the water and there's no railroad to guide them. In this configuration the vessels travel 6,500 nautical miles across the open ocean to Southeast Asia. But as they approach their destination, they disconnect, splitting up as each unmanned ship goes its own way to conduct independent operations, such as collecting data with a variety of onboard sensors.
Once those operations are complete, the four reunite, form a train and make the return journey home.
This is the Sea Train, and it may not be as far-fetched as it sounds. The Defense Advanced Research Projects Agency is investing in several technologies to make it a reality.
“The goal of the Sea Train program is to be able to develop and demonstrate long-range deployment capabilities for a distributed fleet of medium-sized tactical unmanned vessels,” said Andrew Nuss, DARPA's program manager for Sea Train. “So we're really focusing on ways to enable extended transoceanic transit and long-range naval operations, and the way that we're looking to do that is by taking advantage of some of the efficiencies that we can gain in a system of connected vessels — that's where the name ‘Sea Train' comes from.”
According to DARPA, the current security environment has incentivized the Navy and the Marine Corps to move from a small number of exquisite, large manned platforms to a more distributed fleet structure comprised of smaller vessels, including unmanned platforms that can conduct surveillance and engage in electronic warfare and offensive operations.
While these unmanned vessels are smaller and more agile than their large, manned companions, they are limited by the increased wave-making resistance that plagues smaller vessels. And due to their size, they simply can't carry enough fuel to make the long-range journeys envisioned by DARPA without refueling.
By connecting the vessels — physically or in a formation — the agency hopes the Sea Train can reduce that wave resistance and enable long-range missions.
In February, the agency released a broad agency announcement to find possible vendors. Citing agency practice, Nuss declined to share how many proposals were submitted, although he did say there was significant interest in the announcement. The agency completed its review of any submissions and expects to issue contracts by the end of the fiscal year.
Sea Train is expected to consist of two 18-month periods, where contractors will work to develop and test technologies that could enable the Sea Train concept. The program will culminate with model testing in scaled ocean conditions.
If successful, DARPA hopes to see the technologies adopted by the Navy for its unmanned platforms.
“What we're looking to do is be able to reduce the risk in this unique deployment approach,” Ness said. “And then be able to just deliver that set of solutions to the Navy in the future, to be able to demonstrate to them that there is, potentially, a new way to deploy these vessels, to be able to provide far more operational range without the risk of relying on actual refueling or in-port refueling.”
And while DARPA's effort is focused on medium-sized unmanned vessels — anywhere from 12 to 50 meters in length — the lessons learned could be applied to larger or smaller vessels, manned or unmanned.
https://www.c4isrnet.com/unmanned/2020/06/01/all-aboard-the-sea-train/
Sur le même sujet
-
-
24 juillet 2020 | International, Aérospatial
Dassault Aviation : résultats semestriels 2020
DEFENSE Dassault Aviation : résultats semestriels 2020 Le 23 juillet, Éric Trappier, PDG de Dassault Aviation, a tenu une conférence de presse à l'occasion de l'annonce des résultats semestriels 2020. Le groupe a réalisé un chiffre d'affaires de 2,6 Mds€, (contre 3 Mds€ au premier semestre 2019). Le résultat net s'élève à 87 M€ (contre 286 M€ en 2019). En termes de livraisons, Dassault Aviation a remis 16 Falcon au premier semestre 2020, soit un de moins que sur la même période de 2019. Sur le terrain commercial, 5 commandes de Falcon ont été signées, contre 7 un an plus tôt. Concernant le Rafale, 7 appareils ont été livrés à l'export. M. Trappier a souligné la volonté du groupe de maintenir ses investissements d'avenir. «Nous allons maintenir notre effort de R&D autofinancé en faveur de notre future gamme d'avions d'affaires Falcon : le 6X qui est notre priorité absolue, et le NX, le nouveau Falcon. Car en sortie de crise, nous serons au rendez-vous avec des avions nouveaux. Cela va nous coûter en marge mais ce n'est pas le moment de baisser la garde», a-t-il notamment déclaré. Le Figaro du 24 juillet
-
25 février 2019 | International, Autre défense
A New Layer of Medical Preparedness to Combat Emerging Infectious Disease
DARPA has selected five teams of researchers to support PREventing EMerging Pathogenic Threats (PREEMPT), a 3.5-year program first announced in January 2018 to reinforce traditional medical preparedness by containing viral infectious diseases in animal reservoirs and insect vectors before they can threaten humans. Through studies in secure laboratories and simulated natural environments, the PREEMPT researchers will model how viruses might evolve within animal populations, and assess the safety and efficacy of potential interventions. Autonomous Therapeutics, Inc., Institut Pasteur, Montana State University, The Pirbright Institute, and the University of California, Davis, lead the PREEMPT teams. “DARPA challenges the PREEMPT research community to look far left on the emerging threat timeline and identify opportunities to contain viruses before they ever endanger humans,” said Dr. Brad Ringeisen, the DARPA program manager for PREEMPT. “One of the chief limitations of how infectious disease modeling is currently conducted is that it forecasts the trajectory of an outbreak only after it is underway in people. The best that data can do is inform a public health response, which places the United States in a reactive mode. We require proactive options to keep our troops and the homeland safe from emerging infectious disease threats.” According to the World Health Organization (WHO), approximately 60 percent of emerging infectious diseases reported globally are zoonoses, meaning that they were initially diseases of animals and at some point became capable of infecting people. Zoonotic diseases are responsible for millions of human deaths every year, and the scope of the challenge is increasing due to the densification of livestock production, human encroachment into natural spaces, and upward trends in globalization, temperature, and population. Ebola is a high-profile example of a zoonotic disease. Despite being relatively difficult to spread — requiring direct contact with fluids from infected organisms — a string of outbreaks over the past five years has highlighted the threat it could present once established in densely populated areas. Researchers express even greater concern over the pandemic potential of new strains of the influenza virus and other airborne pathogens. Even in the United States and its territories, where viruses do not frequently emerge directly from animal reservoirs, vector-borne transmission of zoonoses such as West Nile virus disease is on the rise. The 2018 U.S. National Biodefense Strategy directs that it is essential to detect and contain such bio-threats, adopting a proactive posture to improve preparedness while also assessing and managing any biosecurity risks related to possible interventions. “The health of the American people depends on our ability to stem infectious disease outbreaks at their source, wherever and however they occur,” the document states. For the Department of Defense, that obligation extends to protection of deployed service members, who often operate in countries that are “hot spots” for emerging viruses yet lack robust public health infrastructure. The teams DARPA selected for PREEMPT comprise multidisciplinary researchers who bring expertise and field experience from around the world, some of whom represent institutions from nations at high risk from emerging infectious disease. Institutions participating as sub-contractors to DARPA receive funding from the lead organizations except as otherwise noted. The PREEMPT teams proposed to model specific diseases to assess the risk of spillover from animals into humans, identify key bottlenecks in the process as opportunities for intervention, and develop and assess novel, animal- or insect-focused interventions with built-in safety switches to prevent cross-species jump. The teams will collect samples from animal reservoirs in the field for analysis in secure, bio-contained facilities; some teams will also conduct analysis on existing banked samples and datasets. DARPA is not funding the release of PREEMPT interventions into the environment. Autonomous Therapeutics, Inc., under principal investigator Dr. Ariel Weinberger, leads a team made up of CSIRO Australian Animal Health Laboratory; Navy Medical Research Unit-2, funded directly by DARPA; University of California, Los Angeles; University of Chicago Medical School; and University of Texas Medical Branch. The team will study air-borne highly pathogenic avian influenza virus in birds and small mammals, and tick-borne Crimean-Congo hemorrhagic fever virus. The Center for Comparative Medicine and the One Health Institute at the University of California, Davis, under principal investigator Dr. Peter Barry and co-PI Dr. Brian Bird, respectively, lead a team made up of the Leibniz Institute for Experimental Virology; Mount Sinai School of Medicine; Rocky Mountain Laboratories of the National Institutes of Health (NIH), to be funded directly by DARPA; The Vaccine Group, Ltd., a spin-out of University of Plymouth; University of Glasgow; University of Idaho; and University of Western Australia. The team will examine Lassa virus spillover from rodents, and study Ebola virus in rhesus macaques. The Institut Pasteur, under principal investigator Dr. Carla Saleh, leads a team made up of Institut Pasteur International Network partners in Cambodia, Central African Republic, France, French Guiana, Madagascar, and Uruguay; Latham BioPharm Group; and Virginia Polytechnic Institute and State University. The team will study several mosquito-borne arboviruses, which refers broadly to animal or human viruses transmitted by insects, as well as mosquito-specific viruses that could interfere with arbovirus infection in the insect vector. Montana State University, under principal investigator Dr. Raina Plowright, leads a team made up of the Cary Institute of Ecosystem Studies; Colorado State University; Cornell University; Griffith University; Johns Hopkins University; NIH's Rocky Mountain Laboratories, funded directly by DARPA; Pennsylvania State University; Texas Tech University; University of California, Berkeley; University of California, Los Angeles; and University of Cambridge. The team will study henipavirus spillover from bats. The henipavirus genus of viruses contains multiple biothreat agents as categorized by NIH and the Centers for Disease Control and Prevention (CDC). The Pirbright Institute, under principal investigator Dr. Luke Alphey, leads a team made up of the University of Nottingham and the University of Tartu. The team seeks to disrupt mosquito transmission of flaviviruses, which include Dengue fever, West Nile, and Zika viruses. Modeling and quantification are as important as new experimental technologies in preventing cross-species jumps. The results from modeling will inform when, where, and at what levels such interventions could be applied to achieve the greatest health benefits. Interventions under consideration include animal- or insect-targeted vaccines, therapeutic interfering particles, gene editors, and indirect approaches informed by environmental and ecological factors that affect how viruses are spread — for instance, understanding the environmental stressors that drive bats into closer contact with humans and devising mitigating options to reduce the likelihood of that contact. The research teams' approaches each come with a unique set of potential benefits and challenges, and the teams are responsible for assessing and demonstrating to DARPA the safety, efficacy, stability, and controllability of their proposed interventions. In the future, these considerations could factor into decisions by the ultimate end users — communities, governments, and regulators — on which strategies to pursue to prevent new zoonoses. DARPA and the PREEMPT teams receive guidance from independent expert advisors in the ethical, legal, social, and regulatory aspects of the life sciences. These individuals include Dr. Claudia Emerson, director of the Institute on Ethics & Policy for Innovation at McMaster University; Dr. Matt Kasper, legislative liaison for the U.S. Navy's Bureau of Medicine and Surgery, and a former deputy director of field laboratory operations at the Naval Medical Research Center; and Dr. Steve Monroe, associate director for Laboratory Science and Safety at the CDC, and a former deputy director of the CDC's National Center for Emerging and Zoonotic Infectious Diseases. The teams also benefit from established relationships with local universities, communities, and governments based on prior or ongoing research. These relationships will facilitate initial field collection and help to familiarize stakeholders with PREEMPT technologies as they are being developed. DARPA is also beginning outreach to the WHO as a potential avenue for future transition of PREEMPT technologies. DARPA intends that PREEMPT teams will perform fundamental research and publish results for review by the broader scientific community. https://www.darpa.mil/news-events/2019-02-19